人类免疫缺陷病毒与乙型肝炎病毒共感染的抗病毒治疗研究进展

Research Progress in Antiviral Therapy for Co-infection of Human Immunodeficiency Virus and Hepatitis B Virus

人类免疫缺陷病毒(human immunodeficiency virus,HIV)和乙型肝炎病毒(hepatitis B virus,HBV)感染均具有较强的社会危害性,二者传播途径相似,故临床上较易出现HIV-HBV共感染情况。随着HIV早期筛查和抗病毒治疗的广泛覆盖,HIV感染者的生存期大大延长。然而相关研究显示,即使能够有效抑制HIV和HBV的复制,HIV-HBV共感染者的发病率和病死率还是明显高于HIV或HBV单独感染者。面对如此挑战,笔者综述了针对HIV或HBV感染的抗病毒药物和治疗方案,旨在为HIV-HBV共感染患者的临床治疗提供参考。

Infection of human immunodeficiency virus(HIV) and infection of hepatitis B virus(HBV) are both infectious diseases with strong social harm, in similar transmission routes, so HIV-HBV co-infection is more likely to occur in clinical practice. With the extensive HIV early screening and antiviral treatment, the survival period of people infected with HIV has been greatly prolonged. However, studies have shown that, even if HIV and HBV replication can be effectively inhibited, the incidence rate and mortality of persons co-infected with HIV/HBV are significantly higher than those of persons affected with HIV or HBV alone. In the face of such challenges, the author summarizes antiviral drugs and treatment regimens for HIV or HBV infection, aiming to provide reference for clinical treatment of persons co-infected with HIV/HBV.